Plan estratégico de Scotiabank Perú del 2016 al 2020

En el presente documento se desarrolla la aplicación del Plan Estratégico de Scotiabank Perú (Scotiabank) dentro de un horizonte de cinco años, con lo que se busca posicionar al Scotiabank como el banco más rentable del Perú además ser el segundo en monto de créditos y depósitos. Este Plan Estratégico se ha iniciado dando a conocer la visión, misión, valores, código de ética para Scotiabank. Luego de un exhaustivo análisis de los factores externos e internos que pueden afectar al Scotiabank, las cuales han permitido identificar ocho oportunidades y siete amenazas que influencian al Scotiabank. Del análisis del sistema financiero peruano y a nivel de otros países se han identificado siete factores claves de éxito. Del análisis interno de Scotiabank donde se tiene en cuenta las áreas de (a) administración, (b) marketing, (c) operaciones, (d) finanzas, (e) recursos humanos, (f) sistemas de información, y (g) tecnología se obtuvieron nueve fortalezas y cinco debilidades. Asimismo, luego de desarrollar las diferentes matrices, se pudieron establecer las siguientes estrategias externas alternativas intensivas y de diversificación: (a) desarrollo de producto, (b) penetración en el mercado, y (c) Diversificación horizontal, estrategias que permitan llevar al Scotiabank en el 2020 a ser el banco más rentable, manteniendo un nivel de riesgo controlado y además aportando al crecimiento del país, de una manera transparente, eficiente y socialmente responsable, todo ello para poder cumplir con su visión, dentro del cual se han establecido cinco objetivos a largo plazo: (a) incremento de ingresos financieros, (b) incremento de utilidades, (c) incremento del ROE, (d) incrementar la participación de mercado de créditos, y (e) incrementar la participación de mercado de depósitos. Entonces, con el cumplimiento de estos cinco objetivos a largo plazo, además de cumplir; en primer lugar; con los objetivos de corto plazo (OCP), Scotiabank conseguirá ser el banco más rentable y el segundo en montos de créditos y depósitos en el Perú.In this document the implementation of the Strategic Plan of Scotiabank Peru (Scotiabank) is developed within a five-year horizon, which seeks to position the Scotiabank as the most profitable bank in Peru also be the second in amount of loans and deposits.This Strategic Plan has started making known the vision, mission, values, Code of Ethics for Scotiabank. After a thorough analysis of external and internal factors, which can affect Scotiabank, it allowed identifying eight opportunities and seven threats that influence Scotiabank. From the Peruvian Financing System and at the level of other countries, seven key success factors were identified. From the internal analysis of Scotiabank, where areas such as (a) administration, (b) marketing, (c) operations, (d) financing, (e) human resources, (f) information systems, and (g) technology are taken into account, nine strengths and five weaknesses were obtained. Likewise, after developing the different matrix, the following alternative intensive external and diversification strategies could be established: (a) product development, (b) market penetration, and (c) horizontal Diversification, strategies which lead Scotiabank to become the most profitable bank by 2020, maintaining a controlled level of risk as well as contributing to the growing of the country in a open, efficient and in a socially responsible way, all this in order to fulfill its vision, within which five long-term objectives have been established: (a) increasing of financial income, (b) increasing of profits, (c) increasing of ROE, (d) increase the participation of credit market, and (e) increase the participation of deposit market. Then, with the implementation of these five long-term goals, in addition to; first; with short-term objectives (OCP), Scotiabank get to be the most profitable bank and the second in amounts of loans and deposits in Peru.Tesi

Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period

COVAD survey 2 long-term outcomes: unmet need and protocol

Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups

COVAD survey 2 long-term outcomes: unmet need and protocol

Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups

Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys

Objective: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs), however hesitancy continues to persist among these patients.Therefore, we studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods: The 1st and 2nd COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analyzed using regression models in different groups. Results: We analyzed data from 18,882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) [OR 0.26; 95%CI: 0.24-0.30, p < 0.001]. However, concerns/fear over long-term safety had increased [OR 3.6;95% CI:2.9-4.6, p < 0.01].We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs [OR:1.8; 95%CI: 1.08-3.2, p = 0.023] and HCs [OR: 4; 95%CI: 1.9-8.1, p < 0.001], as well as more long-term safety concerns/fear [IIMs vs AIRDs; OR: 1.9; 95%CI: 1.2-2.9, p = 0.001; IIMs vs HCs; OR: 5.4 95%CI: 3-9.6), p < 0.001].Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function

COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases